revenue our to call guidance call. provided and ago, exceeding February. everyone, our short afternoon, time reported Good first adjusted earnings welcome we on quarter A with earnings the quarter Angie. XXXX in Thanks, and results EBITDA XXXX fourth quarter our we first
we path and reaffirming range year to announced and adjusted raising a profitability, taking positive our steps million our our our XXXX second XXXX accelerate quarter also are EBITDA to additional guidance strategy million to revenue advance $X full further of We guidance, restructuring $X providing our XXXX guidance. negative to
in our first financial strategy Chief continued highlights thrilled quarter the and X-pillar and we has first Officer. profit more for I'm then we this progress, progress In to promoted is to year actions. discuss On the the Christoforou, commercial of of second are been full quarter, detail advancing addition, making Chris announce guidance and X-pillar results restructuring Operating our in quarter our quarter XXXX.
In results. Rod discuss first provide strategy, the will our market overall call, advance I'll additional that and to including execution, the our today's on from and reflected penetration
are our an as $XXX.X increased device. number was basis. product currency an newest a by X.X% and replacement long-term ago the year for suitable compared growth shift HFX as was For period, This of well this first the a mix to worldwide on now iQ year-over-year driven to constant who increase reported of a SCS revenue million, X.X% and largely as quarter candidates year basis on generation platform, of net
batteries long eventually with a rechargeable But replacement. reminder, in case, a very our functional devices this even require life. devices we believe As have these
will many high-frequency want our and accessing therapy a Nevro years XX patients more. Our of believe or successful newer earliest through our device. patients are now continue out to about We unique
it may slightly believe a small currently implant larger over is in our role this While play of volumes business, a we part SCS time. our
the SCS our SCS compared mainly overall the fusion down largely among trials the period. customers ago year the First, impact with quarter; in softness line trialing This was U.S. our day in interest take with driven approximately or U.S. SI for by out and expectations joint second, attending were X.X% X and in in which physicians practice a of training activity of X. sessions, factors:
added accommodate to the learn more procedure. In quarter fact, we this demand training to in physician sessions
of SI training additional sessions joint and the conducting the remainder are quarter throughout second We the year.
track combined perspective, on minutes, four, year sell such continued to in beginning superior SI as This this one, business our by devices growing leveraging into discuss will million our and the second to half indications therapy two, joint business SI factors show a realize million. year as: in growth competitive expanded which full competitive the Rod revenue we us market physicians; revenue solid through our the our with on to the guidance From cadence joint $XXX such our growing with selling quarter; traction achieve and guidance confidence of as few expectations. more in $XXX can accounts, half several of a our focus this is three, business our results our early to first in PDN, of our gives SCS year; gains that to continued
million. net million negative $X.X loss reported and a of from $XX.X operations adjusted approximately EBITDA of We also
commercial it in up last of ramp our the business, of year limited continue first half commenced joined and the execution, first in reps relates second strategy, on the our joint the As of pillar to quarter, market who release to we products. Nevro the sales SI
customers our focus of SCS to continue our also benefits We educating superior therapy. on the on
not SCS HFX those alternative in that patients represented permanent a device. To the from fourth to mid-April, of an iQ physician. of our broaden to system have do solution of a XXXX. iPhone, half multitude for therapy of patients benefits who in increase a including the HFX generation a we this driving the access X% patient smartphone are nearly our more of and quarter quarter, increased newest compatible the total brings XX% launched first iQ, adoption for We implants the with
iQ our in relief and have the get by than traditional real-world HFX input more a As remote to app over shows on their allowing previously faster pain with data use patients system we to patients the those helps back control who communicated, that combination our therapy. cellphone
expect We the this educate adoption on continued HFX as the we therapy. market iQ benefits of
drive into R&D first for newly limited and SI of to where mentioned, as this joint launching acquired business, developing market advance SI Fusion on broader year. also -- strategic and iQ of penetration, continue enhancements indications, appropriate, our our on joint market focused robust on and the our remainder to growth. throughout to targeting additive as new where I In system integrating focus our We pipeline the focus pillar of second our of Joint expanding products our is HFX we quarter, profitable products just to release executing prepared the release we SI the and the commenced the acquisitions market
to X.X SCS joint to patient back our Through patients, with Notably, options this we business for and expanding who XX% SI more we In utilized pain, with product patients to able By for have joint offer low joint approximately representing pain we where access. expansion receive SI conditions. opportunity. believe engaging leverage did to patients U.S., pain options million market an chronic previously physicians at annually, in are now are address a our solutions solutions SI joint billion that for of SI have portfolio dysfunction. competitive treatment now different now include pain caused therapeutic previously diagnosis into our needs by the we not is products XX% $X not accounts
During device fixing sales the long-term to that with joint with allow for integrated the NevroX, trans conducted vision technology opportunity quarter, has and our physicians proven stand-alone joint reps focus transfect for several primary training a on we immediately SI SI sessions to our
SI physicians patients they is believe our for more utilize customers treatment from feedback are physicians a than of time sessions for positive, new chronic can took excellent Early NevroX has fusion sessions. their very they an and patients treat joint Many them attended XXX innovative suffering pain. joint procedure our to training been who current Year-to-date, pain. so learn SI our from joint training suffering who products participated to the SI in option
see physician SI and joint entrance particularly for demand on significant our NevroX. training continue products, to We
roll out patients identifying joint are SI products the benefit who trained from in fusion market, we that As physicians across from our we the mechanical the joint an suffer procedure. many that practice could of SI pain back
SI treat team as increases, SCS be joint we SCS Importantly, are our interested to products will drive joint devices. who SI sales force we perform their to in physicians leveraging of products gain should as growth. commercial our greater many physicians adoption to and adoption access Also, might patients, also our fusion train continue procedures to using our implant and
Food include the for thrilled XXX(k) first also to We Drug Vyrsa Administration NevroFix This acquired marks we NevroX are the the clearance February, since as NevroX fusion group. late a granted and that the joint need without SI represents on regulatory we safest in the implant significant advancement a and fusion is it available stand-alone efficient, the most device believe joint year. in and market. SI last effective currently clearance
care nerve painful from PDN on At PDN, focused SCS other company as the under indications. awareness diabetic with market health this of treatment or X%, develop increasing our therapy prevalence. limb technology Diabetes the chronic vision remained variety neuropathy to clinical patients free to underpenetrated, is loss. for with significantly and a remain pain, global As in to lead a we grow and a to market of and data. complications, ulcers continues a burden just including public working innovative are circulation, we can and concern a health diabetic and superior major of reduced damage, It
In that the and improvement months was sensory and published of our effects quarter, Science from amputations diabetes-related ulcerations from Technology. for traumatic in in patients function SENZA-PDN the diabetes the in lower RCT suffering XX demonstrate data can severe risk of Diabetes side Journal first
in our be showing to clinical data leader We of best-in-class developing efficacy superior technology. continue XX-kilohertz the a
to improvements beyond As that proved that to we just ahead obtain observed or of calls, and enrollment we've our in is share controlled pain. to more We're pleased earnings outstands our PDN sensory discussed plan. XXX study our SES sensory objectively designed trial, patients RCT, randomized clinical initial at indication an in prior the on
allow subjects in sensory this As demonstrated this existing enrollment to strong primary pausing from the cohort. the are in randomized endpoint enrollment of we PDN study who analysis our a all outcomes are SENZA-RCT, robust result, in
publication in future, inclusion our of is for bring restarting While the may the for patients analysis the to possible benefit review therapeutic indicate in to of trial guidelines. results enrollment and as results as soon goal the
good key progress become and in facility manufacturing made and more as expand EBITDA maintaining The is disciplined We executing quarter, strategy initiatives third our ahead management pillar remain Costa margin demonstrated on coming efficient, profit progress. Rica profitable by focused expectations. expense of our our to front of to first this adjusted growth. on achieve the scaling We in
and We Nevro are make a that steps our advance taking and accelerate restructuring can healthier additional profitability. our so we to nimbler company X-pillar path stronger, strategy to
with laser-focused key and our profitability. areas identified on are and initiatives that growth will We our aligning our drive cost and and business believe managing expenses structure we
additional invest of treatment R&D EBITDA of positive $X We we therapies negative in to the $X Rod full suffering for develop patients guidance in continue for million. guidance are adjusted our will of our innovative quarter our commercialize to and detail, a pain. result to year to but restructuring pipeline year, performance, range steps as discuss this outlook first chronic a million and more our raising remainder from
As I'm the of that newly announce been part created Christoforou Operating to to has Chief promoted these role Chris steps, Officer. this of thrilled
to In time, our right responsibilities into this of proven knowledge and processes leading integration addition in this innovation make our the have leadership choice Nevro development affairs our efforts member and of the oversight research, operations. deep clinical a serve him valuable skills, be X His during and his technological med assurance. the well to manufacturing experience as Chris and of team. for years, strong been he role. spearheading with industry Chris regulatory and now has tech quality will Vyrsa has as and to of
more manufacturing We continue that time. Rica, to more in margin see our Rica Costa over Costa produced expansion is of to as to our our sell increased manufacture down second expect by and we and we source transition inventory facility, supplier
tuck-in facility, we supported as business leverage acquisitions. as technology our we Costa by as manufacturing which We Rica experts through best-in-class is products and grow new develop our will well also
in have excited In since as to CEO, joined our about summary, made progress I We're advancing in entered drivers fusion year future SCS we that our Vyrsa of on fast-growing the market, opportunities ahead we've over SI the as acquisition growth SI through are the significant further market our X-pillar and including past us. focused company the fusion as position for strategy of the Nevro indications We well multiple our joint as joint up through market. business. ramping expanded
our to drive outcomes, will long-term ourselves continue on capitalize deliver produces flow to positive superior leverage unique differentiate We XX-kilohertz that continue meaningful through and opportunities value. generate will profitability, technology shareholder cash to we and
over quarter quarter results the and of financial to guidance. turn Rod XXXX a our call now discussion second first will full I and year for
